Workflow
柳药集团(603368) - 2022 Q3 - 季度财报
LZYYLZYY(SH:603368)2022-10-26 16:00

Financial Performance - The company's operating revenue for Q3 2022 reached ¥5,020,747,654.50, representing a year-on-year increase of 10.20%[4] - The net profit attributable to shareholders for Q3 2022 was ¥206,196,794.01, reflecting a year-on-year growth of 22.02%[4] - For the first nine months of 2022, the company achieved a total operating revenue of ¥14,222,353,645.12, up 10.43% compared to the same period last year[9] - The net profit attributable to shareholders for the first nine months was ¥575,282,231.96, an increase of 15.42% year-on-year[9] - Total operating revenue for the first three quarters of 2022 reached ¥14,222,353,645.12, an increase of 10.4% compared to ¥12,879,074,190.59 in the same period of 2021[31] - Operating profit for the first three quarters of 2022 was ¥703,874,388.02, up from ¥641,552,229.61 in 2021, reflecting a growth of 9.7%[33] - Net profit attributable to shareholders of the parent company for the first three quarters of 2022 was ¥575,282,231.96, compared to ¥498,405,259.79 in 2021, marking a 15.4% increase[36] - The company reported a total profit of ¥705,254,116.41 for the first three quarters of 2022, compared to ¥643,565,280.58 in 2021, which is an increase of 9.6%[33] Revenue Breakdown - The wholesale segment contributed ¥1,158,579.01 million in revenue, with a year-on-year growth of 10.89%, accounting for 81.65% of total revenue[12] - The retail segment generated ¥208,140.79 million in revenue, growing by 4.04% year-on-year, and contributed 14.67% to total revenue[12] - The industrial segment saw a significant increase of 34.26% in revenue, totaling ¥50,712.10 million, and accounted for 3.57% of total revenue[12] Earnings and Shareholder Information - The company reported a basic earnings per share of ¥0.57 for Q3 2022, up 21.28% from the previous year[7] - Basic earnings per share for the first three quarters of 2022 were ¥1.59, up from ¥1.38 in the same period of 2021[36] - The total number of common shareholders at the end of the reporting period is 33,563[19] - The largest shareholder, Zhu Chaoyang, holds 101,032,795 shares, representing 27.89% of total shares[19] Assets and Liabilities - Total assets as of the end of Q3 2022 were ¥19,244,313,979.40, a 21.23% increase from the end of the previous year[7] - The company's total current assets as of September 30, 2022, amount to ¥16,804,534,755.31, an increase from ¥13,387,644,715.92 in the previous year[24] - The total assets of the company reached ¥19,244,313,979.40, up from ¥15,874,750,518.75 year-over-year[26] - The total liabilities of the company as of September 30, 2022, are ¥11,519,785,932.90, compared to ¥8,628,845,690.78 in the previous year[26] - Total liabilities increased to ¥13,004,695,634.15 in Q3 2022 from ¥10,068,480,649.28 in Q3 2021, representing a growth of 29.3%[30] - Total equity rose to ¥6,239,618,345.25 in Q3 2022, compared to ¥5,806,269,869.47 in Q3 2021, an increase of 7.4%[30] Cash Flow and Expenses - Cash flow from operating activities for the first three quarters of 2022 was ¥13,825,860,388.27, compared to ¥11,939,194,061.36 in 2021, indicating a growth of 15.8%[37] - The net cash flow from operating activities was 10,340,035.79, a significant improvement from -1,028,540,254.79 in the previous period[40] - Total cash inflow from financing activities reached 4,632,274,456.75, compared to 2,994,800,891.37 in the prior year, indicating a 54.7% increase[43] - Cash outflow for financing activities was 4,052,445,244.81, up from 3,085,200,019.64, reflecting a 31.4% increase[43] - The net cash flow from financing activities was 579,829,211.94, a turnaround from -90,399,128.27 in the previous year[43] - The total cash and cash equivalents at the end of the period stood at 3,039,360,326.43, down from 2,026,637,390.46, showing a decrease of 49.8%[43] - Cash paid for purchasing goods and services was 12,768,321,413.75, compared to 12,054,545,914.70, marking an increase of 5.9%[40] - Cash paid to employees was 332,300,863.07, slightly up from 315,620,332.86, indicating a 5.3% increase[40] - Cash paid for taxes was 372,193,322.31, which is a 26.7% increase from 293,649,053.12 in the previous period[40] - Cash inflow from investment activities was 110,455,135.55, down from 261,364,678.90, reflecting a decrease of 57.7%[40] - The net cash flow from investment activities was -812,569,194.70, worsening from -321,214,160.00 in the previous year[40] Research and Development - The company has completed the filing of approximately 230 varieties for its traditional Chinese medicine granule production project, accelerating the registration process[9] - Research and development expenses increased to ¥13,938,268.89 in 2022 from ¥7,475,147.19 in 2021, reflecting an increase of 86.5%[31]